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Abstract: A previous proteomic screen in our laboratory identified nuclear factor 45 (NF45) and
nuclear factor 90 (NF90) as potential cellular factors involved in human immunodeficiency virus
type 1 (HIV-1) replication. Both are RNA binding proteins that regulate gene expression; and
NF90 has been shown to regulate the expression of cyclin T1 which is required for Tat-dependent
trans-activation of viral gene expression. In this study the roles of NF45 and NF90 in HIV replication
were investigated through overexpression studies. Ectopic expression of either factor potentiated HIV
infection, gene expression, and virus production. Deletion of the RNA binding domains of NF45 and
NF90 diminished the enhancement of HIV infection and gene expression. Both proteins were found
to interact with the HIV RNA. RNA decay assays demonstrated that NF90, but not NF45, increased
the half-life of the HIV RNA. Overall, these studies indicate that both NF45 and NF90 potentiate HIV
infection through their RNA binding domains.
Keywords: HIV; NF45; NF90; transcription; RNA regulation

1. Introduction
Like all viruses, human immunodeficiency virus (HIV) requires host cell factors for productive
replication. HIV produces only 15 proteins but replicates in several cell lineages and exhibits a complex
life cycle [1]. In addition, the host cell elicits an innate response to defend against viral infection
and spread. Characterization of both the pro- and anti-viral factors during infection may discover
new targets for the development of novel therapeutic strategies that inhibit virus replication and/or
pathogenesis. A number of genetic and proteomic studies have been undertaken to identify cellular
factors involved in HIV replication and the current National Institutes of Health (NIH) interaction
database contains greater than 3000 proteins [2]. Given the size of the database, it is disappointing that
only one antiviral compound targeting a cell factor, Maroviroc, has been approved for clinical use as
an anti-viral inhibitor [3].
Our laboratory has completed a number of proteomic screens for HIV factors [4–6]. Nuclear factor
45 and nuclear factor 90 (NF45 and NF90, respectively) were identified as candidate HIV factors in a
screen of HIV nucleoprotein complexes [5]. These proteins are the products of the interleukin enhancer
binding factor 2 and 3 genes (ILF2 and 3, respectively). Both proteins participate extensively in RNA
metabolism, including the regulation of messenger, noncoding, and regulatory RNAs. NF45 and
NF90 are distinct proteins, but share common domains (Figure 1). NF45 has an N-terminal arginineand glycine rich (RGG) domain at position 3–22, and a domain associated with zinc fingers (DZF) at
position 104–338. NF90 has an N-terminal DZF and C-terminal RGG domain. It also has a defined
nuclear localization signal as well as two double stranded RNA binding (DRBM) motifs. In addition
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Efficient HIV gene expression requires hyperphosphorylation of RNA polymerase II by the
Efficient HIV gene expression requires hyperphosphorylation of RNA polymerase II by the
Positive Transcription Elongation Factor b (P-TEFb), a complex of CDK9 and cyclin T1 [14–17].
Positive Transcription Elongation Factor b (P-TEFb), a complex of CDK9 and cyclin T1 [14–17].
Recruitment of P-TEFb is accomplished by the HIV regulatory protein Tat, which binds the small
Recruitment of P-TEFb is accomplished by the HIV regulatory protein Tat, which binds the small
step-loop trans-activation response element region (TAR) in the 5′1 end of the new synthesized viral
step-loop trans-activation response element region (TAR) in the 5 end of the new synthesized viral
RNA. NF90 has been identified as a regulator of HIV transcription by modulating cyclin T1
RNA. NF90 has been identified as a regulator of HIV transcription by modulating cyclin T1 expression.
expression. Cyclin T1 expression requires binding of NF90
to the 3′ UTR of its mRNA. Therefore,
Cyclin T1 expression requires binding of NF90 to the 31 UTR of its mRNA. Therefore, knockdown
knockdown of NF90 decreases HIV gene expression by reducing cyclin T1 levels [18]. Overexpression
of NF90 decreases HIV gene expression by reducing cyclin T1 levels [18]. Overexpression of NF90
of NF90 can increase HIV promoter activity when co-transfected with an HIV reporter virus [13,18].
can increase HIV promoter activity when co-transfected with an HIV reporter virus [13,18]. Other
Other studies have investigated the role of a C-terminal mutant of NF90 (NF90ctv). Expression of this
studies have investigated the role of a C-terminal mutant of NF90 (NF90ctv). Expression of this mutant
mutant disrupts Tat-dependent transcription by competitive binding of the TAR element [19]. It also
disrupts Tat-dependent transcription by competitive binding of the TAR element [19]. It also interacts
interacts with HIV Rev and inhibits its RNA export activity [20]. Although a later study demonstrated
with HIV Rev and inhibits its RNA export activity [20]. Although a later study demonstrated that
that NF90ctv facilitated the export of gag mRNA in a Rev-independent manner [21]. However, the
NF90ctv facilitated the export of gag mRNA in a Rev-independent manner [21]. However, the NF90ctv
NF90ctv isoform is not expressed in cells and may not be biologically relevant [18,22].
isoform is not expressed in cells and may not be biologically relevant [18,22].
Combined, previous studies show that NF90 is required for HIV gene expression by regulating
Combined, previous studies show that NF90 is required for HIV gene expression by regulating
cyclin T1 expression. In this study, we further investigated the roles of NF45 and NF90 in HIV
cyclin T1 expression. In this study, we further investigated the roles of NF45 and NF90 in HIV
replication using overexpression studies. Our results show that both proteins promote HIV infection.
replication using overexpression studies. Our results show that both proteins promote HIV infection.
The RNA binding domains were required for the effect as deletion of RGG domain in NF45 or
The RNA binding domains were required for the effect as deletion of RGG domain in NF45 or deletion
deletion of DRBMs in NF90 reduced any potentiation. Notably, the overexpression of either protein
of DRBMs in NF90 reduced any potentiation. Notably, the overexpression of either protein did not
did not affect Cyclin T1 levels in cells. NF45 and NF90 were also found to bind HIV RNA in vitro,
affect Cyclin T1 levels in cells. NF45 and NF90 were also found to bind HIV RNA in vitro, although the
although the interactions appear to be sequence independent. Finally, RNA stability assays
interactions appear to be sequence independent. Finally, RNA stability assays demonstrated that NF90
demonstrated that NF90 increased the half-life of HIV RNA, suggesting a second mechanism for the
increased the half-life of HIV RNA, suggesting a second mechanism for the enhancement of HIV gene
enhancement of HIV gene expression. Combined with previous studies, these results show NF45 and
NF90 can potentiate HIV infection and define additional mechanisms by which NF45 and NF90
modulate HIV gene expression.
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expression. Combined with previous studies, these results show NF45 and NF90 can potentiate HIV
infection and define additional mechanisms by which NF45 and NF90 modulate HIV gene expression.
2. Materials and Methods
2.1. Cell Culture
293T and HeLa Tet-On® 3G cells (Clontech Laboratories, Mountain View, CA, USA) were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% Fetal Clone III (Hyclone,
Logan, UT, USA), 100 U/mL penicillin and 100 µg/mL streptomycin. The media for the HeLa Tet-On®
3G also contained 100 µg/mL G418. All cells were grown at 37 ˝ C with 5% CO2 in humidified incubator.
2.2. Proviral Clones and Expression Plasmids
The following plasmids have been described previously: pNLX [23], pNL4-3-Luc [24,25],
pSV2tat72 [26] and pBlue31 LTR-Luc [27,28]. pCMV-NF45 was purchased from OriGene (OriGene,
Rockville, MD, USA). pEF6-NF90 was constructed by subcloning the NF90 ORF from pCMV-Sport6
(Thermo Fisher Scientific Inc., Waltham, MA, USA) into pEF6-TOPO by TOPO cloning
(Life Technologies, Carlsbad, CA, USA) using primers 51 -ATGCGTCCAATGCGAATTTTTGTGAA
TG-31 and 51 -CTAGGAAGACCCAAAATCATGATAG-31 . pTarget-NF45 ∆RGG was constructed by
amplifying a truncated version of NF45 with the RGG region deleted and an artificial start codon
(underlined) inserted (primers: 51 -ACCATGTTCAGGCCCTTTG-31 and 51 -CTAGGAAGACCCAAAA
TCATGATAG-31 ). The amplicon was TA cloned into pTarget (Promega, Madison, WI, USA).
pTarget-NF90 ∆CT was similarly subcloned from pEF6-NF90 using 51 -ATGCGTCCAATGCGAATTTTT
GTGAATG-31 and a 31 primer with a premature stop codon (underlined; 51 -TTACCCGTCCTC
CTCCATTGGGCGTTT-31 ). The deletion mutant, pTarget-NF90 ∆DRBM, was constructed by PCR
overlap mutagenesis using the overlapping primers 51 -GGGCGAGAGGGGTGTCTGCCTTCTC
CTCTTTCT-31 and 51 -AGAAAGAGGAGAAGGCAGACACCCCTCTCGCCC-31 .
pET28a(+)-NF45 and NF90 were generated by inserting NF45 and NF90 cDNA fragments into
pET28a EcoRI and NotI sites. pTRE-LTR was made by subcloning HIV LTR and R3 region using
primers 51 -CGGGATCCTTTTGCCTGTACTGGG-31 and 51 -CGACGCGTTGCTAGAGATTTTCCACA-31 .
pGEM-T-IL2 was cloned from 293T cell RNA using standard cloning techniques (primers:
51 -GCCTTCTATTTATTTAAATAT-31 and 51 -TTATCAAATTTATTAAATAGTT-31 ). All the plasmids
used in this study were verified by sequencing using the Creighton University biomedical core facility
sequencing service.
2.3. Viral Assays
Viruses were prepared and normalized for infectivity as described previously [4,29]. For HIV
infection assays, 293T cells (~5 ˆ 104 ) were seeded in 24 well plates one day prior to transfection.
For overexpression experiment, cells were transfected with total 0.4 µg expression constructs or
control pcDNA3.1 0.4 µg vector using 1 mg/mL polyethylenimine (PEI). For knockdown experiment,
cells were transfected with small interfering RNAs (siRNAs) targets to NF45 and NF90 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at 1 ng/well in 6-well plates using Genmute reagent as directed
by the manufacturer (SignaGen, Gaithersburg, MD, USA). At 24 h post-transfection cells were infected
with virus for 4 h and the media changed. At 48 hours post-infection (hpi) the cells were lysed
with M-PER (Mammalian Protein Extraction Reagent; Thermo Fisher Scientific). The lysates were
cleared by centrifugation at 10,000ˆ g for 4 min at 4 ˝ C and luciferase (Luc) activity measured
using ONE-Glo™ Luciferase reagent and a GloMax® -96 Microplate Luminometer as directed by
the manufacturer (Promega). The luminometer reading (RLU) for each sample was normalized to
its total protein concentration. To measure virus release from transduced cells, 1 ˆ 105 293T cells
were seeded in 6-well plates one day prior to transfection with 0.5 µg pCMV-NF45 or pEF6-NF90.
At 24 h post-transfection cells were infected with HIV pseudotyped with the vesicular stomatitis virus
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glycoprotein (VSVg) envelope for 4 h and the media changed. For the measurement of virus release
from cells co-transfected with the factors, cells were transfected with 0.5 µg pCMV-NF45, pEF6-NF90
plus 0.1 µg pNLX overnight followed by a media change. Cell supernatants were collected at 8 h post
media change in both experiments. Virus release was measured by in vitro reverse transcription assays
as previously described [30]. For virus expression assays each culture was transfected with expression
construct and control vector pCDNA3.1 0.4 µg plus 0.1 µg pNL4-3-Luc. At 48 h post-transfection,
cells were lysed and analyzed for Luc activity. MTT assays were performed using the CellTiter 96
non-radioactive cell proliferation assay according to the manufacturer’s instructions (Promega).
2.4. Immunobloting
Cell samples were lysed and mixed 1:1 with 2ˆ sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) loading buffer, boiled for 10 min and separated by SDS-PAGE. Proteins
were transferred to polyvinylidene fluoride (PVDF) and detected by Western blot using the following
primary antibodies: anti-NF45 (A-8), anti-actin (I-19) and anti-cyclin T1 (T-18) were all obtained from
Santa Cruz Biotechnology; anti-FLAG (M2) was from Sigma (St. Louis, MO, USA) and the anti-NF90
antibody was from Abgent (San Diego, CA, USA). Primary antibody incubations were 1 h, except
the detection of the NF90 deletion mutants with the Abgent antibody required an increased length of
incubation (>3 h). Incubation (30 min) with HRP conjugated anti-rabbit, anti-mouse IgG secondary
(GE Healthcare, Piscataway, NJ, USA) or anti-goat IgG secondary (Sigma) antibody was used to detect
primary antibody binding, which was visualized by chemiluminescent staining (Pierce Biotechnology,
Waltham, MA, USA). Images were captured using radiographic film, scanned to computer, adjusted
for brightness and contrast if necessary, and cropped for size.
2.5. Immunoprecipitation-RT-PCR Assays
Immunoprecipitation-RT-PCR (IP-RT-PCR) assays were performed essentially as described
previously [31]. The cells were transfected 24 h prior to infection. At 24 hpi cells were washed
and lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium
deoxycholate, 0.2% SDS and 1 mM EDTA). Cell lysates were precleared with agarose beads, then
incubated with anti-FLAG M2 magnetic beads (Sigma-Aldrich, St. Louis, MO, USA) for 12 h at
4 ˝ C with rotation. Beads were washed 4 times with RIPA buffer and split into two tubes—one for
immunoblots and one for RNA isolation. The samples for RNA were treated with proteinase K for
30 min at 37 ˝ C and RNA isolated by acid phenol-chloroform extraction. RNA was reverse transcribed
using MLV RNA reverse transcriptase, and DNA quantified by real-time PCR with gag-specific primers
(51 -GAAGCGCGCACGGCAAGAGGC-31 and 51 -GCACACAATAGAGGACTGCTATTGTA-31 ), using
iTaq Universal SYBR Green Supermix and a Bio-Rad CFX Connect Real-Time PCR detection system.
2.6. Purification of Recombination NF45 and NF90 Proteins and RNA Cross-Linking Assays
Recombinant NF45 and NF90 proteins (rNF45 and rNF90) were expressed in BL21 Escherichia coli
(E. coli) cells (Novagen, Madison, WI, USA). Harvested cells were lysed by EmulsiFlex-C3 (AVESTIN,
Ottawa, ON, USA), and His-tagged fusion proteins were purified under native conditions using
HisPur Cobalt Resin (Thermo Fisher Scientific) following the manufacturer’s protocol. The purity
of fusion proteins was confirmed by SDS-PAGE followed by Coomassie staining. Purified rNF45
and rNF90 proteins were dialyzed and stored in 50 mM Tris-HCl (pH 8.0), 50 mM NaCl and 10%
Glycerol at ´80 ˝ C. The DNA templates for RNA probe production contained the T7 primer sequence
linked to the HIV target sequences. These were synthesized by PCR using a pNLX template or
pGEMT-IL2 template. Primers were as follows: U3 part 1 (sense 51 -TAATACGACTCACTATA
GGGTGGAAGGGCTAATTTGG-31 and antisense 51 -ATGCTGGCTCATAGGGTGTAACAAG-31 ) , U3
part 2 (sense 51 -TAATACGACTCACTATAGGGGCTTGTTACACCCTATG-31 and antisense 51 -CCAG
TACAGGCAAAAAGCAGCTGC-31 ), R (sense 51 -TAATACGACTCACTATAGGGGGTCTCTGGTTAG
A-31 and antisense 51 -TGAGCACTCAAGGCAAGCTTTATTG-31 ), U5 (sense 51 -TAATACGACTTC
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ACTATAGGGAAGTAGTGTGTGCCCCG-31 and antisense 51 -CTGCTAGAGTTTTCCACACTGACT-31 )
and IL-2 31 mRNA (sense 51 -TAATACGACTCACTATAGGGGCCTTCTATTTATTAAATAT and antisense
51 -TTATCAAATTTATTAAATAGTT-31 ).
RNA was generated by in vitro T7 transcription (New England Biolabs, Ipswich, MA, USA) in the
presence of [α-32 P]UTP. Transcribed radiolabeled RNA was purified with a RNA probe purification kit
(Omega Bio-Tek, Norcross, GA, USA), denatured at 80 ˝ C for 10 min in 20 mM Tris-HCl, pH 7.5, 100 mM
NaCl, annealed by slow cooling, and stored at –80 ˝ C. For RNA-binding reactions, 2 µg purified GST,
rNF45 or rNF90 protein was incubated with probes in binding buffer (100 mM KCl, 1 mM MgCl2,
0.5 mM EDTA, 1 mM dithiothreitol, 50 g/mL yeast tRNA, and 10% glycerol) for 30 min at 37 ˝ C.
A probe alone group was used as a negative control. After incubation, reaction samples were irradiated
with 4 ˆ 105 J using UV Stratalinker 1800 (Stratagene, La Jolla, CA, USA). Samples were treated with
0.1 mg/mL RNase A at 37 ˝ C for 30 min, the reaction terminated by boiling 5 min in an equal volume
of 2ˆ sample buffer, and separated by 12% SDS-PAGE. Gels were dried, exposed to phosphorimager
screens overnight and imaged using a Typhoon 9400 phosphorimager (GE Healthcare).
2.7. RNA Decay Assays
The transfection and selection of the pTRE-LTR HeLa Tet-On® 3G Cell Line (HeLa-iLTR) was
performed following the manufacturer’s instructions (Clontech). For RNA decay assays, 1 ˆ 105
HeLa-iLTR cells were seeded into 6-well plates 24 h prior to transfection with 1 µg pCDNA3.1,
pCMV-NF45 or pEF6-NF90 using GenJet™ transfection reagent (SignaGen Laboratories, Rockville, MD,
USA) following the manufacturer’s instructions. At 24 h post transfection 10 ng/mL of doxycycline
was added to induce expression of HIV RNA. After 12 h of induction, the cells were washed
3 times and returned to cDMEM. Total RNA was harvested at 0, 8, 16, 24 and 32 h (Omega Biotech,
Norcross, GA, USA). RNA was reverse transcribed using random primers and cDNA was amplified
using primers (51 -TCTGGCTAACTAGGGAACCCAC-3” and 51 -CTGACTAAAAGGGTCTGAGG-31 ).
Primers designed to 18S RNA were used as an internal control (51 -GTAACCCGTTGAACCCCATT-31
and 51 -CCATCCAATCGGTAGTAGCG-31 ).
3. Results
3.1. The Overexpression of NF45 or NF90 Increases HIV Infection and Virus Production
In a previous proteomic study of HIV reverse transcription and preintegration complexes we
observed changes in the expression of NF45 and NF90 in HIV infected cells by mass spectrometry [5].
Since both NF45 and NF90 are RNA binding proteins, we speculated that they might participate in
the early steps of the HIV life cycle. Our initial approach was to examine the effect of over-expressing
each protein on HIV infection. Cells were transfected with individual expression constructs 24 h
prior to transduction with a HIV luciferase reporter virus (HIV-Luc) pseudotyped with the VSVg.
Overexpression of NF45 led to a modest increase in Luc expression, indicating it enhanced infection
(Figure 2A). NF45 has been shown to interact with the RNA of several viruses [32,33], leading us to
hypothesize that it interacted with HIV RNA. To initially test this hypothesis, we tested if deleting
the RNA binding domain of NF45 would mitigate its ability to enhance HIV infection. A mutant
with a deletion in the N-terminal RGG domain was constructed (∆RGG) and tested in infection
experiments. Deletion of the RGG domain ablated the ability of NF45 to enhance HIV infection
(Figure 2A). To confirm the enhancement effect of NF45 we repeated the infection experiments with
wild-type non-pseudotyped HIV and measured the production of virus from infected cells by reverse
transcription assay (Figure 2B). Similar to the Luc assays, a small, but significant increase in HIV
infection occurred in cells over-expressing NF45.
Next we investigated NF90. Knockdown of NF90 by RNA interference reduces HIV gene
expression and the overexpression of NF90 had already been shown to enhance HIV gene expression
in co-transfection experiments [12,18]. We initially sought to examine the effect of NF90 expression on
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HIV infection. The overexpression of NF90 increased HIV infection in both HIV-Luc infection assays
(Figure 2A) as well as single cycle virus production assays (Figure 2C). Similar to NF45, NF90 has
Viruses 2016, 8, 47
6 of 16
also been implicated in the replication of several RNA viruses [34,35], and we again hypothesized
that NF90
may
beimplicated
eliciting in
itsthe
effects
via RNA
binding.
deletion
predicted
to disrupt
has also
been
replication
of several
RNA Two
viruses
[34,35], mutants
and we again
hypothesized
the RNA
binding
function
of
NF90
were
created
(Figure
1):
one
contained
an
in-frame
deletion
that NF90 may be eliciting its effects via RNA binding. Two deletion mutants predicted to disrupt of
the two
(∆DRBM)
and
the second
was a (Figure
large C-terminal
deletion
that deleted
both
the DRBMs
RNA binding
function
of NF90
were created
1): one contained
an in-frame
deletion
of DRBMs
the
twoRGG
DRBMs
(ΔDRBM)
the second
was
a large C-terminal
deletion that
DRBMs
and
and the
motif
(∆CT).and
Although
the
expression
of the mutants
wasdeleted
not as both
robust
as wild-type
RGG motif
(ΔCT).
Although the
expression
of the infection
mutants was
not as robust
as wild-type
NF90, cells
NF90,the
neither
mutant
significantly
boosted
HIV-Luc
compared
to control
transfected
neither
mutant
significantly
boosted
HIV-Luc
infection
compared
to
control
transfected
(Figure 2A). These data suggested that similar to NF45 the RNA binding function of NF90 wascells
required
(Figure
2A). These
suggested that similar to NF45 the RNA binding function of NF90 was
for the
enhancement
of data
infection.
required for the enhancement of infection.
Notably NF45 binds NF90 via its DZF motif and enhances NF90 activities [36,37]. Since both
Notably NF45 binds NF90 via its DZF motif and enhances NF90 activities [36,37]. Since both
NF45 and NF90 enhanced HIV infection, we next tested if overexpression of both factors together
NF45 and NF90 enhanced HIV infection, we next tested if overexpression of both factors together
would
further
enhance
infection.
ToToour
expressionofof
both
proteins
not provide
would
further
enhance
infection.
oursurprise,
surprise, robust
robust expression
both
proteins
did did
not provide
any substantial
boost
to infection
to NF45
NF45ororNF90
NF90
alone
(Figure
These
any substantial
boost
to infectionlevels
levelscompared
compared to
alone
(Figure
2A).2A).
These
data data
suggested
that that
the factors
maymay
be acting
through
the
pathwaythat
thatisissaturated
saturated by
suggested
the factors
be acting
through
thesame
samemechanism
mechanism or pathway
by overexpression
of either
protein.
overexpression
of either
protein.

Figure
2. NF45
NF90
potentiatehuman
humanimmunodeficiency
immunodeficiency virus
(HIV)
infection.
(A) 293T
cells cells
Figure
2. NF45
andand
NF90
potentiate
virus
(HIV)
infection.
(A) 293T
transfected
indicated
expressionvectors
vectors or
vector
as aas
control.
AfterAfter
were were
transfected
withwith
thethe
indicated
expression
orpcDNA3.1
pcDNA3.1empty
empty
vector
a control.
24 h the cells were infected with vesicular stomatitis virus glycoprotein (VSVg)-pseudotyped
24 h the
cells were infected with vesicular stomatitis virus glycoprotein (VSVg)-pseudotyped HIV-Luc
HIV-Luc reporter virus. At 24 hours post-infection (hpi), the cells were harvested and infection
reporter virus. At 24 h post-infection (hpi), the cells were harvested and infection quantified by Luc
quantified by Luc assay and normalized to protein concentration. Results in this, and all other panels
assay and normalized to protein concentration. Results in this, and all other panels are presented
are presented relative to the control group. Error bars in this and all other figures represent standard
relative
to of
thethe
control
bars in
this
and all other
figures represent
standard
error
mean.group.
Protein Error
expression
was
monitored
by immunoblot
using β-actin
as a error
controlof the
mean.(bottom
Proteinpanels);
expression
was
monitored
by
immunoblot
using
β-actin
as
a
control
(bottom
panels);
(B,C) Single cycle production assays for NF45 and NF90, respectively. Cells
(B,C)pre-transfected
Single cycle production
assays
for NF45
and
respectively.
pre-transfected
with plasmids
to indicated
factors
forNF90,
24 h were
transducedCells
with HIV
pseudotyped with
plasmids
indicated
24 h was
werechanged
transduced
withcells
HIVincubated
pseudotyped
with VSVg.
with to
VSVg.
After factors
4 h thefor
media
and the
an additional
8 h. After
Cell 4 h
supernatants
were collected
and
virus
production
by in
vitro
reverse
transcriptase
assay
as
the media
was changed
and the
cells
incubated
anmeasured
additional
8 h.
Cell
supernatants
were
collected
described
in Materials
and Methods.
Plotsreverse
in all panels
show the total
from three in
independent
and virus
production
measured
by in vitro
transcriptase
assaydata
as described
Materials and
experiments
triplicate
transfections;
blots
are
representative
of experiments
all three experiments.
Methods.
Plots inwith
all panels
show
the total data
from
three
independent
with triplicate
(*
p
<
0.05
and
**
p
<
0.01
by
two-tailed
t-test
in
this
and
all
figures).
transfections; blots are representative of all three experiments. (* p < 0.05 and ** p < 0.01 by two-tailed
t-test in this and all figures).
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It was reported that the knockdown of NF90 by RNA interference reduces cyclin T1 expression
It was reported that the knockdown of NF90 by RNA interference reduces cyclin T1 expression
and decreases HIV gene expression [18]. However, knockdown of NF45 and NF90 has been shown
and decreases HIV gene expression [18]. However, knockdown of NF45 and NF90 has been shown
to retard the cell growth [10], which would reduce viral expression. To revisit this issue, we knocked
to retard the cell growth [10], which would reduce viral expression. To revisit this issue, we knocked
down NF45 or NF90 in 293T cells using siRNAs and performed virus infection and production assays
down NF45 or NF90 in 293T cells using siRNAs and performed virus infection and production assays
as well as MTT assays to monitor cell viability. As shown in Figure 4A, in our hands virus infection
as well as MTT assays to monitor cell viability. As shown in Figure 4A, in our hands virus infection was
was modestly, but not substantially reduced by knockdown of either NF45 or NF90. Virus gene
modestly, but not substantially reduced by knockdown of either NF45 or NF90. Virus gene expression
expression was similarly impacted in co-transfection assays (Figure 4B). However, MTT assays
was similarly impacted in co-transfection assays (Figure 4B). However, MTT assays revealed that
revealed that knockdown of either NF45 or NF90 reduced cell health (Figure 4C), suggesting a
knockdown of either NF45 or NF90 reduced cell health (Figure 4C), suggesting a mechanism for the
mechanism for the loss of infection or production. Immunoblots confirmed the expected reductions
loss of infection or production. Immunoblots confirmed the expected reductions in NF45 and NF90
in NF45 and NF90 expression. We also examined the levels of cyclin T1 in the knockdown cells
expression. We also examined the levels of cyclin T1 in the knockdown cells (Figure 4A, blots). Neither
(Figure 4A, blots). Neither the depletion of NF45, nor, in contrast to previous reports, NF90
the depletion of NF45, nor, in contrast to previous reports, NF90 substantially changed the levels of
substantially changed the levels of cyclin T1 expression in our experiments.
cyclin T1 expression in our experiments.
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of of
NF45
or or
NF90
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HIV
gene
gene expression, we tested if cyclin T1 levels were altered in NF45 or NF90 over-expressing cells. To
expression, we tested if cyclin T1 levels were altered in NF45 or NF90 over-expressing cells. To do
do this, we transfected increasing amounts of either NF45 or NF90 and examined the expression of
this, we transfected increasing amounts of either NF45 or NF90 and examined the expression of cyclin
cyclin T1 by immunoblot. As shown in Figure 5, we did not observe a change in the expression of
T1 by immunoblot. As shown in Figure 5, we did not observe a change in the expression of cyclin
cyclin T1 upon overexpression NF45 (top panels) or NF90 (bottom panels). Therefore, we concluded
T1 upon overexpression NF45 (top panels) or NF90 (bottom panels). Therefore, we concluded that
that the enhancement of HIV infection was not due to an increase in the expression of cyclin T1
theresulting
enhancement
of HIV infection was not due to an increase in the expression of cyclin T1 resulting
in increased promoter activity. We also probed the expression of NF90 upon
in NF45
increased
promoter
Weupon
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the expression Similar
of NF90toupon
overexpressionactivity.
and NF45
NF90 overexpression.
our NF45
initial overexpression
experiments
and
NF45
upon
NF90
overexpression.
Similar
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our
initial
experiments
(Figures
2A
and 3A),ofthe
(Figures 2A and 3A), the overexpression of either factor did not appear to affect the expression
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of
either
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not
appear
to
affect
the
expression
of
the
other.
the other.

Figure 5. Cyclin T1 expression in cells over-expressing NF45 and NF90. 293T cells were transfected
Figure 5. Cyclin T1 expression in cells over-expressing NF45 and NF90. 293T cells were transfected with
with increasing amounts of NF45 (top panels) and NF90 (middle panels). After 24 h, cells were
increasing amounts of NF45 (top panels) and NF90 (middle panels). After 24 h, cells were harvested,
harvested, normalized for protein concentration, and immunoblotted for indicated factors. Data are
normalized for protein concentration, and immunoblotted for indicated factors. Data are representative
representative of duplicate experiments.
of duplicate experiments.

3.2. NF45 and NF90 Interact with HIV RNA
3.2. NF45 and NF90 Interact with HIV RNA
Both NF45 and NF90 are promiscuous RNA binding proteins. NF45 binds single stranded RNA,
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binding
proteins.
NF45 binds
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whereas
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contains
RNA
binding
motifs [37,38].
NF90single
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shownRNA,
to
whereas
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have some
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as it has been RNA
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translation
RNAs to
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selectivity
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todomains
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the translation
of RNAs
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[39].asSince
thebeen
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proteins
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[39]. Since the
RNA bindingthat
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of HIV expression,
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with thefor
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infected
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theHIV
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HIVweexpression,
hypothesized
that
both proteins
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were
pre-transfected
with
FLAG-tagged
constructs
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infected
with
HIV+VSVg
24 h. The cells
HIV
RNA.
To test this we
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IP-RT-PCR
assays
infected
cells.
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The
immunoprecipitates
were
were pre-transfected with FLAG-tagged constructs and infected with HIV+VSVg for 24 h. The cells
proteinase
treated,
and RNA isolatedwith
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phenol: chloroform
The capturewere
of HIV
RNA
were
lysed and
immunoprecipitated
anti-FLAG
beads. The extraction.
immunoprecipitates
proteinase
was detected
by real-time
RT-PCR
using gag-specific
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(FigureThe
6). Numerous
were
treated,
and RNA
isolated by
acid phenol:
chloroform
extraction.
capture of controls
HIV RNA
was
used
to
confirm
the
specificity
of
binding,
including
non-transfected
cells,
cells
inoculated
with
detected by real-time RT-PCR using gag-specific primers (Figure 6). Numerous controls were used to
heat-inactivated
virus,
and immunoprecipitation
with ancells,
isotype
antibody.
The results
confirm
the specificity
of binding,
including non-transfected
cells control
inoculated
with heat-inactivated
showed that both NF45 (Figure 6A) and NF90 (Figure 6B) interacted with HIV RNA. As expected,
virus, and immunoprecipitation with an isotype control antibody. The results showed that both NF45
deletion of the RNA binding domains of either protein resulted in a loss of interaction with HIV RNA.
(Figure 6A) and NF90 (Figure 6B) interacted with HIV RNA. As expected, deletion of the RNA binding
domains of either protein resulted in a loss of interaction with HIV RNA.
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NF45 and NF90 have been shown to interact with other RNA binding proteins through binding
NF45 and NF90 have been shown to interact with other RNA binding proteins through binding
to RNA. For example, the interaction of NF90/110 with the RNA-editing factor, adenosine deaminase
to RNA. For example, the interaction of NF90/110 with the RNA-editing factor, adenosine deaminase
acting on RNA (ADAR) is bridged by dsRNAs [40,41]. Another recent proteomic analysis of
acting on RNA (ADAR) is bridged by dsRNAs [40,41]. Another recent proteomic analysis of NF90 and
NF90 and NF110 binding proteins in mouse brain found that NF90 and NF110 interact
NF110 binding proteins in mouse brain found that NF90 and NF110 interact with numerous hnRNPs,
with numerous hnRNPs, including A/B, A2/B1, A3, D, Q, as well as polypyrimidine tract-binding
including A/B, A2/B1, A3, D, Q, as well as polypyrimidine tract-binding protein-associated-splicing
protein-associated-splicing factor [42]. Therefore it is possible that the NF45 and NF90/110 might
factor [42]. Therefore it is possible that the NF45 and NF90/110 might interact with HIV RNA indirectly
interact with HIV RNA indirectly by binding other RNA binding proteins. To determine if NF45 or
by binding other RNA binding proteins. To determine if NF45 or NF90 bound directly to HIV RNA,
NF90 bound directly to HIV RNA, we performed in vitro cross-linking assays. Recombinant,
we performed in vitro cross-linking assays. Recombinant, HIS-tagged NF45 and NF90 were expressed
HIS-tagged NF45 and NF90 were expressed in E. coli and purified by affinity chromatography
in E. coli and purified by affinity chromatography (Figure 7A). Since both NF45 and NF90 may enhance
(Figure 7A). Since both NF45 and NF90 may enhance the transcription of the HIV promoter activity,
the transcription of the HIV promoter activity, it suggested that the proteins may bind the 51 end of
it suggested that the proteins may bind the 5′ end of the HIV RNA. Therefore, the RNA probes were
the HIV RNA. Therefore, the RNA probes were designed to cover the LTR region of HIV-1, including
designed to cover the LTR region of HIV-1, including the R and U5 regions (Figure 7B). We also
the R and U5 regions (Figure 7B). We also constructed two probes covering the U3 region of the LTR
constructed two probes covering the U3 region of the LTR which is present only in the 3′ end of the
which is present only in the 31 end of the HIV mRNA. RNA probes were made by in vitro transcription
HIV mRNA. RNA probes were made by in vitro transcription and labeled with [32P]-UTP. After
and labeled with [32 P]-UTP. After incubation at 37 ˝ C, protein-radiolabeled RNA complexes were
incubation at 37 °C, protein-radiolabeled RNA complexes were UV-crosslinked, digested by RNase,
UV-crosslinked, digested by RNase, separated by SDS-PAGE, and imaged using a phosphorimager.
separated by SDS-PAGE, and imaged using a phosphorimager. In all experiments the 3′ UTR of the
In all experiments the 31 UTR of the IL-2 mRNA was used as a positive RNA probe control [43], and
IL-2 mRNA was used as a positive RNA probe control [43], and purified GST protein was used as a
purified GST protein was used as a negative input protein control. As seen in Figure 7C, we detected
negative input protein control. As seen in Figure 7C, we detected the interaction of NF45 with RNAs
the interaction of NF45 with RNAs from the U3 and TAR regions of the HIV LTR (arrows), but not
from the U3 and TAR regions of the HIV LTR (arrows), but not the U5 region. The non-specific bands
the U5 region. The non-specific bands may represent incompletely digested RNAs or cross-linking to
may represent incompletely digested RNAs or cross-linking to background proteins in the protein
background proteins in the protein preparations. NF90 cross-linked to RNAs from the 51 half of U3
preparations. NF90 cross-linked to RNAs from the 5′ half of U3 and the TAR region (Figure 7D), but
and the TAR region (Figure 7D), but not the 31 half of U3 or the U5 regions. These results indicate that
not the 3′ half of U3 or the U5 regions. These results indicate that NF45 and NF90 bind HIV RNA, but
NF45 and NF90 bind HIV RNA, but the binding of multiple regions of the RNA suggested that the
the binding of multiple regions of the RNA suggested that the interactions were not sequence specific.
interactions were not sequence specific.
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Figure 7. In vitro RNA cross-linking assays. (A) Expression of purified rNF45 and rNF90 visualized
Figure
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assays. blue;
(A) Expression
purified rNF45
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by
SDS-PAGE
andRNA
staining
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of integrated
HIV visualized
DNA and
by
SDS-PAGE
and
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blue;
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Cartoon
depiction
of
integrated
DNA and
mRNA. Approximate locations of RNA probes used in cross-linking assays are shownHIV
at bottom
(C)
mRNA.
Approximate
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RNA
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assays
are
shown
at
bottom
(C)
In vitro RNA binding assays with rNF45 (C) and rNF90 (D). Recombinant proteins were incubated
In
vitro
RNA
binding
assays
with
rNF45
(C)
and
rNF90
(D).
Recombinant
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were
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1
with radiolabeled RNA probes to regions indicated at top (IL2 3 UTR was used as a positive control).
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regions indicated
at with
top (IL2
3′ UTR
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A prior
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SDSGels were imaged using a phosphorimager. Arrows indicate expected migration for HIS-tagged
PAGE.
Gels (D)
were
imaged using a phosphorimager. Arrows indicate expected migration for
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proteins.
HIS-tagged NF45 (C) and NF90 (D) proteins.

3.3. NF90 Stabilizes HIV LTR-Containing RNA in Vivo
3.3. NF90 Stabilizes HIV LTR-Containing RNA in Vivo
Protein expression can be affected by many factors including the half-life of the mRNA. NF90
Protein expression can be affected by many factors including the half-life of the mRNA. NF90 is
is known to stabilize the interleukin-2 mRNA by binding to the AU-rich element located within IL-2
known to1 stabilize the interleukin-2 mRNA by binding to the AU-rich element located within IL-2
mRNA 3 -UTR [43]. The phosphorylation of NF90 Ser647 is critical for this effect [44]. Since we
mRNA 3′-UTR [43]. The phosphorylation of NF90 Ser647 is critical for this effect [44]. Since we
observed that NF45 and NF90 bind HIV RNA, we sought to determine if either factor affected the
observed that NF45 and NF90 bind HIV RNA, we sought to determine if either factor affected the
stability of the RNA. Treatment with the RNA transcription inhibitor actinomycin D (ActD) is a widely
stability of the RNA. Treatment with the RNA transcription inhibitor actinomycin D (ActD) is a
used approach to study RNA decay, but low levels have been shown to upregulate HIV expression due
widely used approach to study RNA decay, but low levels have been shown to upregulate HIV
to hyper-phosphorylation of C-terminal domain of RNA polymerase II [45,46]. Therefore, to measure
expression due to hyper-phosphorylation of C-terminal domain of RNA polymerase II [45,46].
HIV RNA decay we constructed a minimal inducible construct containing the HIV TAR and R3
Therefore, to measure HIV RNA decay we constructed a minimal inducible construct containing the
RNA regions under control of tetracycline response element (pTRE-LTR). The construct was stably
HIV TAR and R3 RNA regions under control of tetracycline response element (pTRE-LTR). The
transfected into HeLa Tet-On® 3G Cell Line and the expression of the HIV RNA element was induced
construct was stably transfected into HeLa Tet-On® 3G Cell Line and the expression of the HIV RNA
by addition of doxycycline (Dox; Figure 8A). Thus, upon removal of Dox RNA transcription ceases
element was induced by addition of doxycycline (Dox; Figure 8A). Thus, upon removal of Dox RNA
and the decay rate of the RNA could be measured by real-time RT-PCR. To test if NF45 or NF90
transcription ceases and the decay rate of the RNA could be measured by real-time RT-PCR. To test
impacted RNA stability, we transfected NF45 and NF90 24 h prior to the addition of Dox. After
if NF45 or NF90 impacted RNA stability, we transfected NF45 and NF90 24 h prior to the addition of
Dox. After 12 h of Dox treatment the cells were washed and RNA then harvested at 0, 8, 16, 24 and
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knockdown
of NF90ofimpaired
HIV gene
[18]; however,
it hasit been
shown
thatthat
the
that
the knockdown
NF90 impaired
HIVexpression
gene expression
[18]; however,
has been
shown
knockdown
of
NF90
significantly
impacts
cell
growth
[10].
Moreover,
NF90
knockout
mice
die
within
the knockdown of NF90 significantly impacts cell growth [10]. Moreover, NF90 knockout mice
12 hwithin
due to12
neuromuscular
respiratory respiratory
failure [11]. failure
Therefore,
is possibleitthat
loss of cell
die
h due to neuromuscular
[11].itTherefore,
is possible
thatviability
loss of
caused
the
reduction
in
HIV
infection
irrespective
of
protein
function.
Indeed,
in
our
experiments,
cell viability caused the reduction in HIV infection irrespective of protein function. Indeed, in our
the loss of infection
upon
knockdown
ofknockdown
either NF45 of
or either
NF90 correlated
withcorrelated
a loss of cell
viability.
experiments,
the loss
of infection
upon
NF45 or NF90
with
a loss
Therefore
the
major
focus
of
these
studies
was
to
examine
the
effects
of
positive
expression
of these
of cell viability. Therefore the major focus of these studies was to examine the effects of positive
proteins. We
found
that NF45
and NF90
potentiated
infectionHIV
by infection
promoting
HIV gene
expression
of these
proteins.
We found
that NF45
and NF90HIV
potentiated
by promoting
expression.
Notably,
neither
overexpression
nor
knockdown
of
NF45
or
NF90
appeared
to affect
HIV gene expression. Notably, neither overexpression nor knockdown of NF45 or NF90 appeared
cyclin
T1cyclin
expression
in our studies,
quantitative
studies are studies
necessary
definitively
to
affect
T1 expression
in ouralthough
studies, further
although
further quantitative
aretonecessary
to
address
this
issue.
The
RNA
binding
domains
of
both
proteins
were
required
to
potentiate
HIV
definitively address this issue. The RNA binding domains of both proteins were required to potentiate
expression.
Both NF45
NF90
bind to
HIV
RNA
in vitro,
the interactions
appeared
HIV
expression.
Both and
NF45
andwere
NF90found
were to
found
bind
HIV
RNAbut
in vitro,
but the interactions
to be non-specific.
Finally, overexpression
of NF90,ofbut
not but
NF45,
the decay
of an of
RNA
appeared
to be non-specific.
Finally, overexpression
NF90,
not slowed
NF45, slowed
the decay
an
containing
HIV
LTR
elements.
Combined
these
data
indicate
that
both
NF45
and
NF90
are
positive
RNA containing HIV LTR elements. Combined these data indicate that both NF45 and NF90 are
regulators
of HIV of
transcription.
NF90 may
HIV gene
expression
by stabilizing
the
positive
regulators
HIV transcription.
NF90also
mayupregulate
also upregulate
HIV gene
expression
by stabilizing
HIV RNA. The role of NF45 RNA binding remains unclear. Interestingly, overexpression of both
proteins did not have an additive effect on HIV gene expression. This suggests both proteins may act
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the HIV RNA. The role of NF45 RNA binding remains unclear. Interestingly, overexpression of both
proteins did not have an additive effect on HIV gene expression. This suggests both proteins may
act independently in the same pathway. Alternatively, the addition of one or the other factor may be
sufficient to saturate effector sites on the HIV RNA or interactions with cellular factors that stimulate
HIV gene expression [37]. Further studies with mutants known to disrupt the NF45-NF90 interface
would clarify this issue [9,37].
The pleiotropic effects of NF45 and NF90 on HIV expression were not surprising as these
are multifunction nuclear proteins that regulate cellular gene expression at different levels [47–49].
These functions include DNA damage repair mediated by DNA-PK [7], RNA translation [39,50] and
microRNA biogenesis [51,52]. Indeed, NF45 and NF90 have been shown to alter the replication cycles
of a number of viruses. NF90 interacts with the 51 end of the hepatitis C virus RNA and is necessary
for efficient virus replication [53]. NF90 binds the 31 end of dengue virus RNA and potentiates virus
replication [35]. The overexpression of NF90 inhibits influenza virus replication during the early phase
of infection through an interaction with the viral nucleoprotein [34]. NF45 accumulates at sites of
replication of infectious bursa disease virus (IBDV) and it may negatively regulate IBDV replication as
siRNA knockdown of NF45 enhances replication [33]. It has also been found that knockdown of NF45
or NF90 restores the expression of the p53 and p21 proteins in cervical carcinoma cells infected with
high-risk human papillomaviruses (HPVs) [47]. It has also been shown that NF90 is a component of
stress granules, which possess antiviral activity [54].
While our data suggest that NF45 and NF90 increase HIV production through interactions with
HIV RNA, we cannot exclude the possibility that they may control the expression of other host factors
and lead to an enhancement of infection. Proteomic analyses of the NF90/110 interactome show
interactions with a number of RNA processing proteins, including numerous Heterogeneous nuclear
ribonucleoproteins (hnRNPs) [42]. NF90 has also been shown to interact with the anti-viral factor
PKR, which is known to be inhibited during HIV infection [55,56]. It could be possible that the
overexpression of NF90 alters PKR activity in a manner that enhances HIV infection. The transcription
factor YY1 is another HIV factor that interacts with NF90 [57,58]. YY1 has been shown to repress
LTR activity; therefore, NF90 overexpression may sequester this factor and lead to increased viral
gene expression. Further studies that compare the interactomes of NF45 and NF90 in uninfected
and HIV infected cells are needed to address this issue and identify other factors that may alter HIV
gene expression.
The NF90ctv C-terminal variant of NF90 was shown to reduce HIV gene expression by competing
with Tat for binding to TAR RNA [19]. Our data confirmed that NF90 binds TAR, but show clearly
that overexpression of NF90 potentiates HIV gene expression. Combined with previous data [18], we
believe these results convincing show that NF90 is a positive regulator HIV infection. It may be that the
alteration in the C-terminus of NF90ctv may create a dominant negative mutant of HIV transcription.
Lastly, in contrast to Hoque et al. we found that NF45 potentiates HIV transcription and infection
using two independent experimental systems. This discrepancy may be due to the variability in
methodology including the cell lines (HeLa vs. 293T), strains of virus used, or the nature of the NF45
expression vectors used. NF45 has been shown to interact with the RNA of several viruses. In addition
to IBDV, NF45 was found to bind the IRES of rhinovirus type 2 and inhibit translation [59]. It has also
been shown to interact with the hepatitis C capsid protein via a RNA intermediate [60], although the
functional consequence of this interaction is unknown. We show that NF45 enhances HIV infection
by upregulating HIV gene expression, and we observed that it bound HIV RNA but did not alter
its stability. We do not yet know how NF45 increases HIV infection. It may potentiate translation,
or activate gene expression through a cellular pathway. Further studies will be needed to delineate the
role of NF45 in HIV replication.
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